Drug Trial Radar · NCT05597839
Study of DF9001 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 15, 2022
Primary completion
Aug 15, 2025
Study completion Aug 15, 2025
Sponsor
- Lead sponsor
- Dragonfly TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors (monotherapy and in combination with pembrolizumab).
Conditions
- Solid Tumor, Adult
Interventions
DF9001Drug
Immunotherapy agent targeting NK cells.
KEYTRUDA® (pembrolizumab)Drug
Anti-PD-1 immunotherapy agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number, severity, and duration of treatment-related adverse events (TRAEs) according to NCI-CTCAE v5.0.Time frame: Screening visit up to 28 days after last treatment on the study.
- Number of patients with AEs and TRAEs.Time frame: Screening visit up to 28 days after last treatment on the study.
- Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocolTime frame: First 4 weeks of treatment for each subject.
- Assess Overall Response RateTime frame: Through 90 days after completion of the study, an average of 1 year.
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson
Gilbert, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
UC Irvine Medical Center
Irvine, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Mayo Clinic Jacksonville
Jacksonville, Florida
University of Louisville Hospital
Louisville, Kentucky
Mayo Clinic Minnesota
Rochester, Minnesota
AMR Kansas City
Kansas City, Missouri
Rutgers
New Brunswick, New Jersey
Icahn School of Medicine at Mount Sinai
New York, New York
University of Cincinnati
Cincinnati, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
Virginia Cancer Specialists
Fairfax, Virginia
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.